CJC-1295 (link:https://www.bloomtechz.com/synthetic-chemical/peptide/cjc-1295-acetate-cas-863288-34-0.html) is a synthetic growth hormone-releasing hormone (GHRH) polypeptide, which is a synthetic drug developed at the Schulman Institute. This compound can enhance the secretion of growth hormone (GH) in the body and help reduce obesity, increase the body's metabolic rate and lipoxygenase activity, etc. With further research on CJC-1295, it was found that the half-life of CJC-1295 containing DAC is longer than that of CJC-1295 without DAC, and has different characteristics in some application directions. In the following, we will detail the difference between CJC-1295 with and without DAC.
CJC-1295 contains the definition of DAC:
CJC-1295 contains DAC, a polypeptide chain consisting of the GHRH analog CJC-1295 and a stabilized peptide chain appendage (DAC). GHRH is a hormone that stimulates the release of GH in the body, while DAC is an addendum that enhances the stability of the peptide chain.
The role of CJC-1295 is to promote growth in the body by stimulating the pituitary gland to secrete GH, and it can also reduce insulin levels, increase glycogen breakdown, and reduce fat accumulation. However, CJC-1295 has a short half-life in the body and requires frequent injections to exert a long-lasting therapeutic effect.
To overcome this problem, the scientists added a stabilizing peptide chain appendage (DAC) and combined it with CJC-1295 to form CJC-1295 containing DAC. DAC can enhance the stability of CJC-1295, make it stay longer in the body, and improve the bioavailability of CJC-1295.
Half-life of CJC-1295 with and without DAC:
The main difference between CJC-1295 with and without DAC is the length of the half-life. The half-life of CJC-1295 without DAC is only about 30 minutes, while the half-life of CJC-1295 with DAC can be as long as more than 7 days, and it stays in the body for a longer time.
Because CJC-1295 contains DAC with a longer half-life, its plasma concentration changes more slowly, requiring fewer injections to maintain efficacy. In addition, the DAC contained in CJC-1295 also helps to achieve a more stable and long-lasting growth hormone release.
Bioavailability of CJC-1295 with and without DAC:
The bioavailability of CJC-1295 with DAC is generally higher than that of CJC-1295 without DAC. This is because DAC can improve the stability of the polypeptide chain, thereby making CJC-1295 more resistant to enzymatic hydrolysis in the body and absorbing more drug molecules.
At the same time, the long-acting nature of CJC-1295 containing DAC also allows it to be more fully utilized, and a wider range of pharmacological effects can be obtained at the same dose.
Dosage and injection frequency of CJC-1295 with and without DAC:
Since CJC-1295 contains DAC with a longer half-life, when used, a smaller dose can be used to obtain the same effect. At the same time, the number of injections per course of treatment can also be reduced, which can reduce the burden on patients and improve treatment compliance.
For example, the standard dosage of CJC-1295 containing DAC is 1000~2000mcg each time, which usually needs to be injected once a week. The standard dosage of CJC-1295 without DAC is 30~60mcg each time, usually requiring several injections per day.
Applications of CJC-1295 with and without DAC:
Both CJC-1295 with and without DAC are effective GHRH analogues, but they have different characteristics in the direction of application.
1. Weight management and obesity treatment:
Both CJC-1295 with and without DAC have certain effects on weight management and obesity treatment. They both promote lipoxygenase activity, accelerate metabolic rate, and reduce body weight and fat accumulation, among other things.
2. Diabetes treatment:
CJC-1295 with or without DAC can stimulate the secretion of growth hormone, promote the production and release of insulin, and can improve the function of pancreatic islet cells. However, since CJC-1295 contains DAC with longer half-life and higher bioavailability, it may be more practical in diabetes treatment.
3. Immunomodulation:
Both CJC-1295 containing DAC and without DAC can promote the proliferation and differentiation of immune cells, and enhance the resistance of cells to external stimuli. Among them, the therapeutic effect of CJC-1295 containing DAC may be more durable.
4. Anti-aging:
Both CJC-1295 with and without DAC can slow down the aging process and prolong lifespan by promoting the secretion of growth hormone. However, CJC-1295 contains DAC with a longer half-life and higher bioavailability, so it may perform more significantly in anti-aging.
5. Cell repair:
CJC-1295, with or without DAC, can promote cell proliferation and repair, thereby helping to treat certain diseases, such as muscle atrophy, osteoporosis, trauma and inflammation. Since CJC-1295 contains DAC with longer half-life and higher bioavailability, it may also perform more prominently in cell repair.
In summary, the differences between CJC-1295 containing DAC and not containing DAC are mainly in half-life, bioavailability, dosage and injection frequency. Both are effective GHRH analogues, but in practical applications, it is necessary to choose the appropriate drug according to the specific situation. Regardless of whether CJC-1295 contains DAC or does not contain DAC, its use must be carried out under the guidance of a doctor to ensure its safety and effectiveness.